Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease

Hyun Jung Lee, Jong Eun Yeon, Eun Jung Ko, Eileen L. Yoon, Sang Jun Suh, Keunhee Kang, Hae Rim Kim, Seoung Hee Kang, Yang Jae Yoo, Jihye Je, Beom Jae Lee, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Kwan Soo Byun

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

AIM: To evaluate the inflammasome activation and the effect of peroxisome proliferator-activated receptors (PPAR)-δ agonist treatment in nonalcoholic fatty liver disease (NAFLD) models. METHODS: Male C57BL/6J mice were classified according to control or high fat diet (HFD) with or without PPAR-δ agonist (GW) over period of 12 wk [control, HFD, HFD + lipopolysaccharide (LPS), HFD + LPS + GW group]. HepG2 cells were exposed to palmitic acid (PA) and/or LPS in the absence or presence of GW. RESULTS: HFD caused glucose intolerance and hepatic steatosis. In mice fed an HFD with LPS, caspase-1 and interleukin (IL)-1β in the liver were significantly increased. Treatment with GW ameliorated the steatosis and inhibited overexpression of pro-inflammatory cytokines. In HepG2 cells, PA and LPS treatment markedly increased mRNA of several nucleotide-binding and oligomerization domain-like receptor family members (NLRP3, NLRP6, and NLRP10), caspase-1 and IL-1β. PA and LPS also exaggerated reactive oxygen species production. All of the above effects of PA and LPS were reduced by GW. GW also enhanced the phosphorylation of AMPK-α. CONCLUSION: PPAR-δ agonist reduces fatty acidinduced inflammation and steatosis by suppressing inflammasome activation. Targeting the inflammasome by the PPAR-δ agonist may have therapeutic implication for NAFLD.

Original languageEnglish
Pages (from-to)12787-12799
Number of pages13
JournalWorld journal of gastroenterology
Volume21
Issue number45
DOIs
Publication statusPublished - 2015 Dec 7

Keywords

  • Inflammasome
  • Nonalcoholic fatty liver disease
  • Nonalcoholic steatohepatitis
  • Nucleotide-binding and oligomerization domain-like receptor
  • Peroxisome proliferator-activated receptors delta

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease'. Together they form a unique fingerprint.

  • Cite this

    Lee, H. J., Yeon, J. E., Ko, E. J., Yoon, E. L., Suh, S. J., Kang, K., Kim, H. R., Kang, S. H., Yoo, Y. J., Je, J., Lee, B. J., Kim, J. H., Seo, Y. S., Yim, H. J., & Byun, K. S. (2015). Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease. World journal of gastroenterology, 21(45), 12787-12799. https://doi.org/10.3748/wjg.v21.i45.12787